OGN Quote, Financials, Valuation and Earnings

Geron Corp. has a net margin of -13.6% compared to Organon & Co.'s net margin of -39.02%. Organon & Co.'s return on equity of 79.63% beat Geron Corp.'s return on equity of -29.65%.

Organon & Co. has a consensus price target of $9.21, signalling upside risk potential of 13.76%. On the other hand Geron Corp. has an analysts' consensus of $3.40 which suggests that it could grow by 80.85%. Given that Geron Corp. has higher upside potential than Organon & Co., analysts believe Geron Corp. is more attractive than Organon & Co..

Organon & Co. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Geron Corp. has a beta of 0.620, suggesting its less volatile than the S&P 500 by 38.038%.

Organon & Co. has a quarterly dividend of $0.02 per share corresponding to a yield of 4.2%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & Co. pays 47.22% of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend. Organon & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & Co. quarterly revenues are $1.5B, which are larger than Geron Corp. quarterly revenues of $47.2M. Organon & Co.'s net income of -$205M is lower than Geron Corp.'s net income of -$18.4M. Notably, Organon & Co.'s price-to-earnings ratio is 11.30x while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & Co. is 0.34x versus 6.83x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -13.6% compared to Organon & Co.'s net margin of 18.06%. Organon & Co.'s return on equity of 79.63% beat Merck & Co., Inc.'s return on equity of 39.63%.

Organon & Co. has a consensus price target of $9.21, signalling upside risk potential of 13.76%. On the other hand Merck & Co., Inc. has an analysts' consensus of $126.00 which suggests that it could grow by 3.06%. Given that Organon & Co. has higher upside potential than Merck & Co., Inc., analysts believe Organon & Co. is more attractive than Merck & Co., Inc..

Organon & Co. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Organon & Co. has a quarterly dividend of $0.02 per share corresponding to a yield of 4.2%. Merck & Co., Inc. offers a yield of 2.68% to investors and pays a quarterly dividend of $0.85 per share. Organon & Co. pays 47.22% of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & Co. quarterly revenues are $1.5B, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Organon & Co.'s net income of -$205M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Organon & Co.'s price-to-earnings ratio is 11.30x while Merck & Co., Inc.'s PE ratio is 16.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & Co. is 0.34x versus 4.72x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -13.6% compared to Organon & Co.'s net margin of -316.61%. Organon & Co.'s return on equity of 79.63% beat Plus Therapeutics, Inc.'s return on equity of --.

Organon & Co. has a consensus price target of $9.21, signalling upside risk potential of 13.76%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1900%. Given that Plus Therapeutics, Inc. has higher upside potential than Organon & Co., analysts believe Plus Therapeutics, Inc. is more attractive than Organon & Co..

Organon & Co. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Organon & Co. has a quarterly dividend of $0.02 per share corresponding to a yield of 4.2%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & Co. pays 47.22% of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend. Organon & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & Co. quarterly revenues are $1.5B, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Organon & Co.'s net income of -$205M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Organon & Co.'s price-to-earnings ratio is 11.30x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & Co. is 0.34x versus 4.41x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -13.6% compared to Organon & Co.'s net margin of 21.74%. Organon & Co.'s return on equity of 79.63% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Organon & Co. has a consensus price target of $9.21, signalling upside risk potential of 13.76%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $869.96 which suggests that it could grow by 11.58%. Given that Organon & Co. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Organon & Co. is more attractive than Regeneron Pharmaceuticals, Inc..

Organon & Co. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Organon & Co. has a quarterly dividend of $0.02 per share corresponding to a yield of 4.2%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.46% to investors and pays a quarterly dividend of $0.94 per share. Organon & Co. pays 47.22% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & Co. quarterly revenues are $1.5B, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Organon & Co.'s net income of -$205M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Organon & Co.'s price-to-earnings ratio is 11.30x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & Co. is 0.34x versus 5.90x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.